Renal CD14 expression correlates with the progression of cystic kidney disease

Kidney International

Volumn 78, Issue 6, 2010, Pages 550-560

  Zhou, Juling ^a   Ouyang, Xiaosen ^a   Cui, Xiangqin ^a,b   Schoeb, Trenton R ^b   Smythies, Lesley E ^a   Johnson, Martin R ^c   Guay Woodford, Lisa M ^b   Chapman, Arlene B ^d   Mrug, Michal ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarkers; CD14; cpk mouse; innate immune response; polycystic kidney disease

Indexed keywords

CD14 ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; GENE EXPRESSION; IMMUNE RESPONSE; INNATE IMMUNITY; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE EPITHELIUM; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL;

EID: 77956231407     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.175     Document Type: Article

References (54)

1. Gabow P. Autosomal dominant polycystic kidney disease. N Eng J Med 1993; 329: 332-342.
2. The European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1 gene encodes a 14kb transcript and lies within a duplicated region on chromosome 16. Cell 1994; 77: 881-894.
3. The American PKD1 Consortium. Analysis of the genomic sequence for the autosomal dominant polycystic kidney disease (PKD1) gene predicts the presence of a leucine-rich repeat. Hum Mol Genet 1995; 4: 575-582.
4. The International Polycystic Kidney Disease Consortium. Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. Cell 1995; 8: 289-298.
5. Mochizuki T, Wu G, Hayashi T et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 1996; 272: 1339-1342.
6. Onuchic L, Furu L, Nagasawa Y et al. PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple IPT domains and PbH1 repeats. Am J Hum Genet 2002; 70: 1305-1317.
7. Ward C, Hogan M, Rossetti S et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 2002; 30: 259-269.
8. Zeier M, Fehrenbach P, Geberth S et al. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 1992; 42: 1259-1265.
9. Cowley Jr BD, Ricardo SD, Nagao S et al. Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats. Kidney Int 2001; 60: 2087-2096.
10. Zheng D, Wolfe M, Cowley Jr BD et al. Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2003; 14: 2588-2595.
11. Mrug M, Zhou J, Woo Y et al. Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. Kidney Int 2008; 73: 63-76.
12. Gattone V, Cowley Jr BD, Barash B et al. Methylprednisolone retards the progression of inherited polycystic kidney disease in rodents. Am J Kidney Dis 1995; 25: 302-313.
13. Mei C, Wang L, Xiong X et al. Experimental research on the treatment of autosomal dominant polycystic kidney disease with mycophenolate mofetil. J Am Soc Nehrol 2007; 18: 364A.
14. Shillingford JM, Murcia NS, Larson CH et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103: 5466-5471.
15. Li X, Magenheimer BS, Xia S et al. A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat Med 2008; 14: 863-868.
16. Mrug M, Li R, Cui X et al. Kinesin family member 12 is a candidate polycystic kidney disease modifier in the cpk mouse. J Am Soc Nephrol 2005; 16: 905-916.
17. Grantham J. Mechanisms of progression in autosomal dominant polycystic kidney disease. Kidney Int 1997; 63: S93-S97.
18. Torres VE. New insights into polycystic kidney disease and its treatment. Curr Opin Nephrol Hypertens 1998; 7: 159-169.
19. Burtey S, Riera M, Fontes M. Overexpression of complement components genes in Han:SPRD rats a model of polycystic kidney disease. Kidney Int 2008; 73: 1324-1325.
20. Pugin J, Heumann ID, Tomasz A; et al. CD14 is a pattern recognition receptor. Immunity 1994; 1: 509-516.
21. Kim JI, Lee CJ, Jin MS et al. Crystal structure of CD14 and its implications for lipopolysaccharide signaling. J Biol Chem 2005; 280: 11347-11351.
22. Morrissey J, Guo G, McCracken R et al. Induction of CD14 in tubular epithelial cells during kidney disease. J Am Soc Nephrol 2000; 11: 1681-1690.
23. Haziot A, Chen S, Ferrero E et al. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol 1988; 141: 547-552.
24. Bufler P, Stiegler G, Schuchmann M et al. Soluble lipopolysaccharide receptor (CD14) is released via two different mechanisms from human monocytes and CD14 transfectants. Eur J Immunol 1995; 25: 604-610.
25. Jones CA, Holloway JA, Popplewell EJ et al. Reduced soluble CD14 levels in amniotic fluid and breast milk are associated with the subsequent development of atopy, eczema, or both. J Allergy Clin Immunol 2002; 109: 858-866.
26. Bazil V, Strominger JL. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J Immunol 1991; 147: 1567-1574.
27. Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand J Clin Lab Invest Suppl 2008; 241: 89-94.
28. Togbe D, Schnyder-Candrian S, Schnyder B et al. Toll-like receptor and tumour necrosis factor dependent endotoxin-induced acute lung injury. Int J Exp Pathol 2007; 88: 387-391.
29. Verdeguer F, Le Corre S, Fischer E et al. A mitotic transcriptional switch in polycystic kidney disease. Nat Med 2010; 16: 106-110.
30. Pei Y. A 'two-hit' model of cystogenesis in autosomal dominant polycystic kidney disease? Trends Mol Med 2001; 7: 151-156.
31. Bastos AP, Piontek K, Silva AM et al. Pkd1 haploinsufficiency increases renal damage and induces microcyst formation following ischemia/reperfusion. J Am Soc Nephrol 2009; 20: 2389-2402.
32. Sundan A, Gullstein-Jahr T, Otterlei M et al. Soluble CD14 from urine copurifies with a potent inducer of cytokines. Eur J Immunol 1994; 24: 1779-1784.
33. Bussolati B, David S, Cambi V et al. Urinary soluble CD14 mediates human proximal tubular epithelial cell injury induced by LPS. Int J Mol Med 2002; 10: 441-449.
34. Piontek K, Menezes LF, Garcia-Gonzalez MA et al. A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat Med 2007; 13: 1490-1495.
35. Patel V, Li L, Cobo-Stark P et al. Acute kidney injury and aberrant planar cell polarity induce cyst formation in mice lacking renal cilia. Hum Mol Genet 2008; 17: 1578-1590.
36. Torres VE, Harris PC. Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol 2006; 2: 40-55.
37. Malhotra S, Kincade PW. Canonical Wnt pathway signaling suppresses VCAM-1 expression by marrow stromal and hematopoietic cells. Exp Hematol 2009; 37: 19-30.
38. Ruse M, Knaus UG. New players in TLR-mediated innate immunity: PI3K and small Rho GTPases. Immunol Res 2006; 34: 33-48.
39. Hu X, Chen J, Wang L et al. Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J Leukoc Biol 2007; 82: 237-243.
40. Le NH, van der Wal A, van der Bent P et al. Increased activity of activator protein-1 transcription factor components ATF2, c-Jun, and c-Fos in human and mouse autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2005; 16: 2724-2731.
41. Good DW, George T, Watts III BA. Lipopolysaccharide directly alters renal tubule transport through distinct TLR4-dependent pathways in basolateral and apical membranes. Am J Physiol Renal Physiol 2009; 297: F866-F874.
42. Gonzales PA, Pisitkun T, Hoffert JD et al. Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc Nephrol 2009; 20: 363-379.
43. Abiola O, Angel JM, Avner P et al. The nature and identification of quantitative trait loci: a community's view. Nat Rev Genet 2003; 4: 911-916.
44. Karrar A, Broome U, Sodergren T et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology 2007; 132: 1504-1514.
45. Wolfs TG, Buurman WA, van Schadewijk A et al. In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. J Immunol 2002; 168: 1286-1293.
46. Bolignano D, Coppolino G, Campo S et al. Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease. Am J Nephrol 2007; 27: 373-378.
47. Bolignano D, Lacquaniti A, Coppolino G et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 337-344.
48. Kistler AD, Poster D, Krauer F et al. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 2009; 75: 235-241.
49. Kistler AD, Mischak H, Poster D et al. Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int 2009; 76: 89-96.
50. Yamazaki K, Ueki-Maruyama K, Oda T et al. Single-nucleotide polymorphism in the CD14 promoter and periodontal disease expression in a Japanese population. J Dent Res 2003; 82: 612-616.
51. Lodrup Carlsen KC, Lovik M, Granum B et al. Soluble CD14 at 2yr of age: gender-related effects of tobacco smoke exposure, recurrent infections and atopic diseases. Pediatr Allergy Immunol 2006; 17: 304-312.
52. Lynch EA, Dinarello CA, Cannon JG. Gender differences in IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist secretion from mononuclear cells and urinary excretion. J Immunol 1994; 153: 300-306.
53. Hou X, Mrug M, Yoder B et al. Cystin, a novel cilia-associated protein, is disrupted in the cpk mouse model of polycystic kidney disease. J Clin Invest 2002; 109: 533-540.
54. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-680.